Stay up to date with QuantuMDx news and developments

QuantuMDx launches Q-POC™ – rapid, PCR point of care diagnostic system

NEWCASTLE UPON TYNE, UK: QuantuMDx today announces the launch of Q-POC™ – a rapid, PCR point of care diagnostic system. Launching at ECCMID 2021, QuantuMDx’ Q-POC™ system and its first test, a SARS-CoV-2 detection assay, are now CE-IVD marked under the In Vitro Diagnostics Directive (98/79/EC), enabling use within Europe. The Q-POC™ SARS-CoV-2 assay has been evaluated at St George’s, University of London, to assess clinical performance against tests in current use. The Development & Assessment of Rapid Technology (DART)…

Read More

Q-POC™ – one device, endless possibilities.

Q-POC™ offers a rapid PCR point of care testing solution for COVID-19 across a wide range of settings. Our infographic…

Read More

QuantuMDx launches Q-POC™ – rapid, PCR point of care diagnostic system

NEWCASTLE UPON TYNE, UK: QuantuMDx today announces the launch of Q-POC™ – a rapid, PCR point of care diagnostic system.…

Read More

QuantuMDx included on PHE National Microbiology Framework

Diagnostic Goods and Services (Lot 1) Research and Development Goods (Lot 2) NEWCASTLE UPON TYNE, UK, 08 June 2021. QuantuMDx has…

Read More

QuantuMDx appoints Mirre de Noo as Non-Executive Director

NEWCASTLE UPON TYNE, UK, 26 May 2021. QuantuMDx has appointed Mirre de Noo, as a Non-Executive Director. Mirre has over…

Read More

QuantuMDx completes £11m funding round

 NEWCASTLE UPON TYNE, UK, 24th March 2021. QuantuMDx today announces it has raised £11 million in its latest funding round. Proceeds…

Read More

Prime Minister, Boris Johnson visits QuantuMDx

NEWCASTLE UPON TYNE, UK, 13 February 2021. QuantuMDx today welcomed the Prime Minister, Rt Hon Boris Johnson MP, for a tour of…

Read More

QuantuMDx response: Government workplace testing announcement

NEWCASTLE UPON TYNE, UK, 7th February 2021. Statement from Jonathan O’Halloran, Chief Executive Officer, QuantuMDx: QuantuMDx welcomes the news from…

Read More

QuantuMDx’ SARS-CoV-2 test validated for use by NHS Test & Trace

Conclusions verify QuantuMDx’ previous analyses of test performance Results confirm this is one of the most sensitive tests on the…

Read More

QuantuMDx appoints Chief Commercial Officer

NEWCASTLE UPON TYNE, UK, 21 January 2021. QuantuMDx today announces the appointment of Diran Guiliguian as Chief Commercial Officer. Diran…

Read More

QuantuMDx SARS-CoV-2 test detects all discovered variants

NEWCASTLE UPON TYNE, UK, 22 December 2020. QuantuMDx today confirms its diagnostic assay for SARS-CoV-2 remains suitable for detecting all…

Read More

QuantuMDx invests £11 million on scale-up to mass manufacture

NEWCASTLE UPON TYNE, UK, 17 December 2020. QuantuMDx today announced it has invested over £11 million to scale up production of…

Read More

Staff Spotlight: Mark Ware

Meet Mark Ware, Customer Care and Training Manager at QuantuMDx. When did you start working at QuantuMDx?  I started as a…

Read More

Scaling up in a pandemic: A Q&A with Andy Whittle

Andy Whittle, VP Manufacturing at QuantuMDx, discusses the highs and lows of scaling up to manufacture, during a global pandemic.…

Read More

QuantuMDx E-poster presentation: ECCVID 2020

Our Head of Assay Feasibility, Dr John Tyson presented an e-poster at ECCVID last month – the ESCMID Conference on Coronavirus.…

Read More

White paper: QuantuMDx SARS-CoV-2 RT-PCR Detection Assay – clinical performance evaluation

Title: QuantuMDx SARS-CoV-2 RT-PCR Detection Assay – design, analytical and multi-centre evaluation of clinical performance White paper overview: After completing…

Read More

Staff Spotlight: Sam Bhatt

Sam Bhatt is a Programme Manager at QuantuMDx. Here, Sam tells us more about himself and gives us an insight…

Read More

QuantuMDx attains CE-IVD marking for SARS-CoV-2 Test

QuantuMDx Group today announces its SARS-CoV-2 detection assay has been CE-IVD marked under the In Vitro Diagnostics Directive (98/79/EC), enabling…

Read More

QuantuMDx launches rapid, sensitive SARS-CoV-2 test

QuantuMDx Group today announces the launch of its sensitive SARS-CoV-2 assay for laboratory use, which delivers a result in approximately…

Read More

Request a Demo

Complete the form below if you’d like to request a demo.

Consent(Required)
This field is for validation purposes and should be left unchanged.